Format

Send to

Choose Destination
Vaccine. 2013 Sep 6;31(39):4235-40. doi: 10.1016/j.vaccine.2013.03.016. Epub 2013 Mar 21.

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.

Author information

1
Lehrstuhl für Virologie, Institut für Infektionsmedizin und Zoonosen, Ludwig-Maximilians-Universität München, Veterinaerstr. 13, 80539 Munich, Germany. asisa.volz@micro.vetmed.uni-muenchen.de

Abstract

Modified Vaccinia virus Ankara (MVA) is a tissue culture-derived, highly attenuated strain of vaccinia virus (VACV) exhibiting characteristic defective replication in cells from mammalian hosts. In the 1960s MVA was originally generated as a candidate virus for safer vaccination against smallpox. Now, MVA is widely used in experimental vaccine development targeting important infectious diseases and cancer. Versatile technologies for genetic engineering, large-scale production, and quality control facilitate R&D of recombinant and non-recombinant MVA vaccines matching today's requirements for new biomedical products. Such vaccines are attractive candidates for delivering antigens from pathogens against which no, or no effective vaccine is available, including emerging infections caused by highly pathogenic influenza viruses, chikungunya virus, West Nile virus or zoonotic orthopoxviruses. Other directions are seeking valuable vaccines against highly complex diseases such as AIDS, malaria, and tuberculosis. Here, we highlight examples of MVA candidate vaccines against infectious diseases, and review the efforts made to assess both the efficacy of vaccination and immune correlates of protection in preclinical studies.

KEYWORDS:

Poxviruses; Preclinical studies; Recombinant MVA vaccines; Vaccine efficacy

PMID:
23523402
DOI:
10.1016/j.vaccine.2013.03.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center